(Total Views: 274)
Posted On: 09/03/2019 2:25:17 PM
Post# of 149117
Ibalizumab got priority review, breakthrough therapy, and orphan drug designations.
They only needed 40 patients and only 27, 43% had VL < 50 at 24 weeks, with no additional safety data needed.
Oct 24 2016, P3 trial results announced SP $2
March 6 2018 Drug approval SP: hit 7.50
May 2018, hit $12
Now SP $3.74.
I will never understand how they got all the special attention, I believe a lot of it was because they were first in p3, but IV is big issue, seems an obvious problem to me, then add the high cost of drug + IV, and smaller MDR3 population, I never got it. I traded it a couple times thanks to Fred on ihub, but the sp was under a dollar in 2015 and hit 12 in 2018 after approval, made like 40%, but with 6x return from p3 results to after drug approval, I missed a great opportunity there. I believe their market is correcting now and ours should soon.
They only needed 40 patients and only 27, 43% had VL < 50 at 24 weeks, with no additional safety data needed.
Oct 24 2016, P3 trial results announced SP $2
March 6 2018 Drug approval SP: hit 7.50
May 2018, hit $12
Now SP $3.74.
I will never understand how they got all the special attention, I believe a lot of it was because they were first in p3, but IV is big issue, seems an obvious problem to me, then add the high cost of drug + IV, and smaller MDR3 population, I never got it. I traded it a couple times thanks to Fred on ihub, but the sp was under a dollar in 2015 and hit 12 in 2018 after approval, made like 40%, but with 6x return from p3 results to after drug approval, I missed a great opportunity there. I believe their market is correcting now and ours should soon.
(2)
(0)Scroll down for more posts ▼
